Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: tiotropium inhalationDrug: salmeterol xinafoateDrug: fluticasone propionateDrug: placebo matched for fluticasone propionate
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2015-02-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2488
- Registration Number
- NCT00975195
- Locations
- 🇭🇺
352.2046.36004 Boehringer Ingelheim Investigational Site, Komarom, Hungary
🇭🇺352.2046.36001 Boehringer Ingelheim Investigational Site, Szarvas, Hungary
🇭🇺352.2046.36006 Boehringer Ingelheim Investigational Site, Pecs, Hungary
Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid Cancers
- Conditions
- Neoplasms
- Interventions
- Drug: BI 6727
- First Posted Date
- 2009-09-01
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 59
- Registration Number
- NCT00969553
- Locations
- 🇨🇳
1230.16.886002 Boehringer Ingelheim Investigational Site, Tainan, Taiwan
🇨🇳1230.16.886001 Boehringer Ingelheim Investigational Site, Taipei, Taiwan
BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour
- Conditions
- Neoplasms
- Interventions
- Drug: BI-6727Drug: BI 6727
- First Posted Date
- 2009-09-01
- Last Posted Date
- 2019-01-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 61
- Registration Number
- NCT00969761
- Locations
- 🇧🇪
1230.6.3201 Boehringer Ingelheim Investigational Site, Bruxelles, Belgium
🇧🇪1230.6.3202 Boehringer Ingelheim Investigational Site, Leuven, Belgium
Study to Evaluate the Safety and Efficacy of Pradaxar for the Prevention of Venous Thromboembolism in the Mexican Population Undergoing Elective Total Hip or Knee Replacement Surgery
- Conditions
- ThromboembolismArthroplasty, Replacement, Hip
- First Posted Date
- 2009-08-27
- Last Posted Date
- 2014-03-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2
- Registration Number
- NCT00967447
- Locations
- 🇲🇽
Boehringer Ingelheim Investigational Site 11, Distrito Federal, Mexico
🇲🇽Boehringer Ingelheim Investigational Site 15, Distrito Federal, Mexico
🇲🇽Boehringer Ingelheim Investigational Site 12, Distrito Federal, Mexico
Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes
- First Posted Date
- 2009-08-07
- Last Posted Date
- 2013-12-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1263
- Registration Number
- NCT00954447
- Locations
- 🇺🇸
1218.36.01005 Boehringer Ingelheim Investigational Site, Statesville, North Carolina, United States
🇦🇷1218.36.54004 Boehringer Ingelheim Investigational Site, Córdoba, Argentina
🇧🇪1218.36.32002 Boehringer Ingelheim Investigational Site, Edegem, Belgium
Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.
- First Posted Date
- 2009-08-03
- Last Posted Date
- 2015-07-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT00950742
- Locations
- 🇬🇧
1200.68.44001 Boehringer Ingelheim Investigational Site, Brighton, United Kingdom
🇬🇧1200.68.44003 Boehringer Ingelheim Investigational Site, Cambridge, United Kingdom
🇬🇧1200.68.44005 Boehringer Ingelheim Investigational Site, Guildford, United Kingdom
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
- Conditions
- Carcinoma, Non-Small-Cell LungAdenocarcinoma
- Interventions
- First Posted Date
- 2009-07-30
- Last Posted Date
- 2018-04-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 345
- Registration Number
- NCT00949650
- Locations
- 🇦🇷
Imcaba S.R.L., Capital Federal, Argentina
🇩🇪Lungenklinik Hemer, Hemer, Germany
🇧🇷Hospital São Lucas da Pontifícia Universidade Católica, Porto Alegre, Brazil
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients
- Conditions
- Hepatitis CPharmacokinetics
- Interventions
- Drug: pegylated interferon (PegIFN) alfa-2aDrug: PlaceboDrug: BI 201335 NA low placeboDrug: ribavirin (RBV)Drug: BI 201335 NA highDrug: BI 201335 NA lowDrug: BI 201335 NA high placebo
- First Posted Date
- 2009-07-28
- Last Posted Date
- 2015-07-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 22
- Registration Number
- NCT00947349
- Locations
- 🇯🇵
1220.14.003 Boehringer Ingelheim Investigational Site, Kurashiki, Okayama, Japan
🇯🇵1220.14.002 Boehringer Ingelheim Investigational Site, Nishinomiya, Hyogo, Japan
🇯🇵1220.14.001 Boehringer Ingelheim Investigational Site, Minato-ku, Tokyo, Japan
Study of Hypertensive Population Under Treatment With Telmisartan in Real Clinical Conditions With the Goal to Control Early Morning Blood Pressure Rise
- Conditions
- Hypertension
- First Posted Date
- 2009-07-27
- Last Posted Date
- 2019-11-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18299
- Registration Number
- NCT00946829
- Locations
- 🇾🇪
Boehringer Ingelheim Investigational Site, Boehringer Ingelheim Investigational Site, Yemen
PRO-POWER: Hypertension With Risk Factors for a Duration of 24 Weeks With Micardis 80mg/Micardis Plus 80mg/12.5mg
- Conditions
- Hypertension
- First Posted Date
- 2009-07-09
- Last Posted Date
- 2014-04-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3184
- Registration Number
- NCT00936208
- Locations
- 🇪🇬
Boehringer Ingelheim Investigational Site 16, Alexandria West, Egypt
🇪🇬Boehringer Ingelheim Investigational Site 21, Alexandria, Egypt
🇪🇬Boehringer Ingelheim Investigational Site 12, Cairo, Egypt